SMNR · Semnur Pharmaceuticals, Inc.
$0.84
+0.04 (+5.01%)
At close · Aug 14
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company's ability to continue as a going concern for one year after the date the condensed consolidated financial statements are issued.”View the 10-Q filed Aug 10, 2026
Market Cap
$193.38M
Shares
230.21M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.84
Open$0.65
Day$0.65–0.86
Available close range$0.35–23.00
Avg vol 30d15K
Short int93K · 0.0% float · 3.6d
Short vol4%
DataSep 2025–Aug 2026
Filing10-Q · Aug 10
The closing range uses available history since Sep 23, 2025; less than a full year is stored.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 10, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Neutral
Sentiment
Bullish
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
−31%
below
RSI (14)
42
neutral
MACD trend
Positive
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+17%
trailing
YTD return
−96%
this year
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.04% of float · ▼ -12.9% MoM · 3.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
2 holders — 13F breadth
Squeeze score
51
elevated · 0–100
Fundamentals
Revenue growth
0%
Y/Y
EPS growth
−3800%
Y/Y
Balance sheet
$6.0M
net debt
Quant / Vol
risk profile
Volatility
498%
annualized · 1-yr
Max drawdown
−98%
past year
ATR
32.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
−31%
Bearish
RSI (14)
42
Neutral
MACD trend
Positive
Bullish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.04% of float · ▼ -12.9% MoM · 3.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
2 holders — 13F breadth
Price context
position in its available closing range
Range low $0
Now $1 · 2%
Range high $23
vs 50-day avg -31%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SMNR
this stock
Semnur Pharmaceuticals, Inc.
|
$193.38M | -96.3% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
2
- % held
- 0.0%
- Net QoQ
- +146 sh
- Top holder
- GAMMA Investing LLC
Held
Float
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SMNR | +1.2% | +16.7% | — | -1.2% | -96.4% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +0.8% | +12.2% | — | -5.1% | -110.2% |